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Abstract
Androgen insensitivity syndrome (AIS) is a rare disease associated with inactivating mutations of AR that disrupt male sexual
differentiation, and cause a spectrum of phenotypic abnormalities having as a common denominator loss of reproductive
viability. No established treatment exists for these conditions, however there are sporadic reports of patients (or
recapitulated mutations in cell lines) that respond to administration of supraphysiologic doses (or pulses) of testosterone or
synthetic ligands. Here, we utilize a novel high content analysis (HCA) approach to study AR function at the single cell level
in genital skin fibroblasts (GSF). We discuss in detail findings in GSF from three historical patients with AIS, which include
identification of novel mechanisms of AR malfunction, and the potential ability to utilize HCA for personalized treatment of
patients affected by this condition.
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Introduction
Androgen action is mediated by the intracellular androgen
receptor (AR), a transcription factor member of the nuclear
receptor superfamily. While in the cytoplasm under baseline
conditions, upon addition of agonist AR translocates to the
nucleus, where it interacts with coregulators and promoters/
enhancers of AR-responsive genes, and regulates transcription.
AR action is a conditio sine qua non for the normal development and
function of the entire male genital tract; conversely, varyingly
degrees of impaired AR action from mutation is causative in
individuals affected by androgen insensitivity syndrome (AIS)
[1,2]. Three main clinical phenotypes in humans define AIS:
Complete, Partial and Minimal Androgen Insensitivity (CAIS,
PAIS and MAIS), and they range from complete lack of
virilization of the internal and external genitalia (CAIS), to
intermediate virilization (PAIS), to apparently normal virilization
in infertile males (MAIS) [1]. A slightly more complex classifica-
tion, describing seven grades of abnormal virilization, has been
proposed by Quigley and collaborators [2]. A data-base of AR
mutations in AIS patients is published on-line (http://androgendb.
mcgill.ca/), and a large body of previous work has defined three
broad varieties of AR
3H-DHT binding abnormalities in
monolayer binding analyses: 1) absent binding (i.e.
3H-DHT
binding is undetectable) [3]; 2) qualitatively abnormal binding
[e.g., binding is normal but with qualitative abnormalities such as
increased ligand dissociation rate (the dissociation rate is
considered abnormal if ,60% of the specific androgen binding
remains after 3 hours) [4]; or thermolability (defined as a
reduction in specific androgen binding at 41uC compared to
37uC of greater than 40%) [5]]; or, 3) decreased binding (e.g.,
binding is detectable but below normal) [1]. The degree of
abnormality caused by each individual mutation is usually related
to the patient phenotype, the
3H-DHT binding characteristics,
and the amount of residual reporter gene activity present in cells
transfected with an AR carrying that particular mutation; in
general, in the more feminized phenotypes, lack of
3H-DHT
binding and abnormal transcriptional activity parallel increasing
AR malfunction.
Despite the clinical dogma that ‘‘AIS is not treatable,’’ some
sporadic PAIS and MAIS patients respond to endocrine
management consisting of pharmacologic doses of androgens
[6–9]. Further, in vitro analysis of some AR mutations with the
binding phenotype of normal
3H-DHT dissociation constant (Kd)
and maximal binding (Bmax), but increased ligand-receptor
dissociation rate can be normalized under certain culture
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acid substitution (Y763C) and a reduced polyglutamine tract (Q12)
normalized its transcriptional activity when exposed to pharma-
cologic concentrations of androgens both in vitro [10] and in vivo
[6]. In other such CAIS or PAIS mutations, transcriptional activity
normalized either after administration of supraphysiologic con-
centrations of endogenous androgens (e.g., testosterone or
dihydrotestosterone, DHT), synthetic androgens (Mibolerone or
R1881), or after treatment with frequent pulses (up to every four
hours) of physiologic doses of DHT [11–13].
Our group has recently developed a high throughput micros-
copy-based technology to simultaneously analyze multiple AR
activities at the single cell level, an approach often referred to as
high content analysis (HCA). Our AR-oriented HCA involves
multi-parametric interrogation of cultured cells using automated
high magnification, high resolution imaging and immunofluores-
cence or green fluorescent protein-fused AR (GFP-AR) in
combination with use of a red fluorescent protein-based
transcriptional reporter protein [14–17]. Utilizing custom-devel-
oped image analysis routines, the datasets can be quantitatively
explored to yield a ‘‘multiplex’’ view of interrelated AR functions.
The image data mining yields information including (but not
limited to) AR expression, subcellular trafficking, reporter gene
activity, cell cycle position, mitotic index, and literally hundreds of
other measurements per cell [15].
We theorized that HCA of AR would be an ideal technology to
directly analyze patient-derived genital skin fibroblasts to identify
not only mechanisms associated with abnormal AR activities, but
also therapeutic options normalizing mutant AR functions. While
there are many AIS mutations described, those localized in the
LBD and associated with 1) normal Kd, 2) normal Bmax, and 3)
qualitative abnormalities of ligand-receptor interaction would be
the most amenable to normalization. We present here unique
cytological profiles generated by HCA from three historical
patients affected by CAIS or PAIS, which were complemented
by NH2-COOH-terminal domain interaction (NC-TDI) experi-
ments, and previously published ligand-binding studies [11]. All
patients carried AR mutations with the specifications listed above.
HCA revealed the type of functional defects associated with these
mutations, and ligand-dependent restoration of AR functions
using experimental conditions that increase the stability of the
ligand receptor complex in two of the three patients. Normaliza-
tion of AR function was associated in each case with improvement
of NC-TDI. These studies provide a proof-of-concept demonstra-
tion that specific clinical mutations of AR can be examined by
HCA for use in personalized medicine.
Methods
Cell Culture
Primary cultures of genital skin fibroblast from AIS patients
F764L, R840C and P766S, and six normal patients were established
aspreviouslydescribed [18],and maintainedinMEMwith 10%FBS
and 1% penicillin and streptomycin. HeLa cells were obtained from
the American Type Culture Collection (Rockville, MD) and were
maintainedinDMEMsupplementedwith5%FBSand1%penicillin
and streptomycin. Control GSF cell lines were isolated at the time of
circumcision from the foreskin of male neonates with normal genital
development, after obtaining approval from the Baylor College of
Medicine Institutional Review Board. No further follow up on these
individuals is available, and it is assumed that normal pubertal
development will be completed, and that their AR sequence is wild
type. Patients with PAIS or CAIS were from the historical library of
AIS patients at UT Southwestern [1].
AIS Mutation Background and Clinical History
The mutations investigated in this study are AR-F764L, AR-
R840C, and AR-P766S. These mutations were previously
identified in patients affected by either PAIS, or CAIS, and
functionally characterized by using either patient derived genital
skin fibroblasts, or after transfection in CV1 or CHO cells [11].
The discrepancies between the coordinates of the mutations
reported in this paper and in the original publication [11] are due
to the use in this publication of the AR coordinates reported in the
AR mutation database online (http://androgendb.mcgill.ca/).
The discrepancies are due to the different number of glutamines
in the polyglutamine region of exon 1 that were reported in the
initial sequences of AR.
Mutation F764L
The F764L mutation was originally identified in a CAIS patient
of Dr. G. Costin (Los Angeles, CA) [11], and has also been
reported in other patients by two additional groups [19,20].
Biochemical studies in transfected CHO cells demonstrated
normal
3H-DHT Kd and Bmax (the Kd was 0.26 nM for the wild
type AR and 0.1 nM for mutant F764L, which is not considered a
meaningful difference), and abnormally elevated ligand dissocia-
tion rate [11]. Using DHT and the MMTV-luc reporter, the
F764L mutation demonstrated significantly decreased transcrip-
tional activity in transfected CV1 cells. Activity was rescued to
nearly 30% of control by the synthetic androgen Mibolerone [11].
Mutation R840C
This mutation has been identified in multiple patients with
PAIS [21–26]. Biochemical studies in transfected CHO cells
demonstrated normal
3H-DHT Bmax and Kd and presence of
thermolability [11]. When examined in transfected CV1 cells, the
transcriptional activity of the R840C mutated receptor was
decreased to 67% of control using DHT [11].
Mutations P766S
This mutation was identified in three patients with CAIS
[11,27,28]. Biochemical characterization in CHO cells revealed
normal Kd and Bmax, and abnormally elevated ligand dissociation
rate. Transcriptional activity was 9% of control in response to
DHT, but normalized at 120% of control in response to
Mibolerone [11].
This historical analysis showed that AR-R840C, AR-F764L and
AR-P766S shared these following common features; they were
point-mutations localized in the ligand binding domain with
normal
3H-DHT Kd and Bmax. According to the series of 130
families published by Dr. Griffin, these features are shared by 40%
of patients with AIS [1].
GFP-AR Expression Vectors and HeLa Stable Cell Lines
cDNA expression vectors for hAR harboring the AIS related
mutations were previously generated [11]. Generation of pEGFP-
AR fusion vectors with an NH2-terminal GFP tag and regulation
by the CMV promoter has been previously described [29]. pEGFP
vectors expressing AR harboring the various AIS mutations were
generated by replacing an EcoRI-Pvul cDNA fragment encoding
the LBD of pEGFP-AR by the same fragment of pAR-F764L,
pAR-R840C, pAR-P766S expression vectors.
A HeLa cell line stably expressing wild type GFP-AR was
previously described [15]. To generate similar cell lines expressing
the various AIS associated mutations, HeLa cells were transfected
with 1 mg/well pEGFP-AR plasmid DNA using BioRad Trans-
fectin reagent 1 day after plating in six-well plates. After 24 hours,
AR HCA in AIS Profiling
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1 mg/mL G418 (Invitrogen) in 10 cm tissue culture dishes. Clones
were selected, expanded, and analyzed by flow cytometry for GFP-
AR expression. Cells with low to moderate GFP-AR expression
were then single cell cloned and expression verified by western
blot; subsequently, GFP-AR expression was found similar to or
below the endogenous expression of AR in the LNCaP prostate
cancer cell line [15].
NH2-COOH-Terminal Domain Interaction (NC-TDI) Assay
An interaction between COOH terminal AF2 (activation
function 2) and NH2 terminal sequence F
23XXLF
27 is an
important step toward the activation of AR [30]. The NC-TDI
was measured using the reagents of the CheckMate
TM/FlexiH
Vector Mammalian Two-Hybrid System, Promega (Madison,
WI). A segment containing AR 1-660 was fused to the VP16 TAD
domain of plasmid pFN10A, while segments AR 624-919 (wild
type or containing mutations F764L, R840C, and P766S) were
fused to the to the Gal4-DBD domain of plasmid pFN11A. The
NC-TDI assay was performed in a similar way as a standard
transactivation assay, except for the expression vectors that were
used. One day before transfection, 1.5610
6 Hela cells were seeded
into a 60 mm dish. Cells were co-transfected with 1.3 ug of
pFN11A-AR624-919, 1.3 ug of pFN10A-1-660, 1.3 ug of
pGL4.31 (containing five GAL4 binding sites upstream of a
minimal TATA box, which is upstream of a firefly luciferase gene
that acts as a reporter for interactions between proteins), and 1 ng
of phRL-TK carrying the Renilla luciferase gene. After 12 hours
of transfection, cells were trypsinized and equally seeded into nine
wells of a 12 well plate, with one well treated with vehicle and
others with various concentration of different ligand. After 24 h of
treatment, luciferase activity was assayed with the Promega Dual
Glo assay kit, using a luminometer (PerkinElmer). Data represent
the average6SD of three independent experiments, are expressed
as fold-induction compared with negative control, and represent
the units of firefly luciferase corrected for the units of renilla
luciferase detected in the same plate.
Preparation of Cell Lines and Experimental Procedure
To determine the global effect of the various AIS mutations on
AR signaling, each was analyzed using HCA. This technology
allows simultaneous quantification of AR protein expression,
nuclear translocation, subnuclear patterning, and transcriptional
activity [15]. The analysis was done in HeLa cell lines stably
transfected with wild type or mutant ARs fused with green
fluorescent protein, or using AR immunofluorescence in primary
cultures of genital skin fibroblasts generated from foreskin biopsies
of historical AIS patients, or of normal neonates undergoing
circumcision at birth. To prevent the effects of receptor over-
expression [15], stable HeLa cells were carefully selected to
express AR levels similar to LNCaP as previously described [15].
Prior to ligand treatment, HeLa cells were transfected with the
pARR2PB-dsRED2skl reporter plasmid, consisting of the AR
responsive promoter ARR2PB [31] driving expression of the red
fluorescent protein reporter dsRED2skl engineered to target
peroxisomes [15]. Stably transfected HeLa cells, containing wild
type or mutant ARs, and GSF cell lines were treated with DHT,
R1881 and Mb at concentrations ranging from 100 to 0.001 nM
for 24 hours.
High Throughput Microscopy – Sample Preparation
For studies utilizing HeLa GFP-AR cell lines, twenty-four hours
before transfection with pARR2PB-dsRED2skl, cells were plated
onto 100 mm plastic dishes in medium supplemented with 5%
charcoal-stripped and dialyzed-FBS. Transient introduction of the
pARR-2PB-dsRED2skl reporter construct was performed using
6.0 mg reporter plasmid and 6.0 mg carrier DNA (BlueScript,
Stratagene, San Diego, CA) using Transfectin (Biorad) following
standard protocols. After 8-hour incubation, DNA/lipid complex-
es were removed. Cells were then trypsinized and replated at
10,000 cells per well in Nunc poly-D-lysine treated 96-well optical
glass bottom plates and incubated an additional 12 hours to allow
for cell adhesion. Cells were then exposed to DHT, R1881 or
Mibolerone for 24 h. Compound dilutions and final addition to
multi-well plates were performed using a Beckman Biomek NX
robotic platform to ensure repeatability from experiment to
experiment. After incubation was complete, using the Biomek NX
robot, plates were washed with PBS and fixed for 20 min at RT in
4% formaldehyde prepared in CSK buffer (80 mM potassium
PIPES, pH 6.8, 5 mM EGTA, 2 mM MgCl2). After fixation, cells
were briefly permeabilized (5 min) with 0.5% Triton-X and
prepared for imaging by washing in PBS, aspirating the washed
solution, and adding a 1 ng/ml DAPI solution to stain DNA and a
generic protein stain (CellMask, Invitrogen) to facilitate cell and
nuclear image segmentation. Cells were imaged in PBS.
For studies utilizing GSF cell lines, cells were treated in an
identical manner except cells were not transfected with the
reporter construct. After ligand incubation was complete, cells
were fixed and endogenous AR was immunolabeled using the
Biomek NX liquid handling robot. Cells were initially washed in
PBS buffer and fixed for 30 min on ice in 4% formaldehyde
prepared in CSK buffer. After fixation, auto-fluorescence was
quenched using a 0.1 M NH4Cl solution for 10 minutes. Next,
cells were permeabilized (30 min) with 0.5% Triton-X. After
washing, cells were incubated for 30 minutes in 5% non-fat milk in
Tris buffered Saline (TBS)-Tween (Blotto) followed by an
overnight incubation in Blotto containing a 1 mg/ml anti-AR
mouse monoclonal antibody (AR ms IgG [32], a kind gift from Dr.
Dean Edwards, Baylor College of Medicine). The primary
antibody was labeled using an anti-ms IgG Alexa488 secondary,
fixed and prepared for imaging by washing in PBS, aspirated and
then washed, then adding a 1 ng/ml DAPI/CellMask solution.
Cells were imaged in PBS.
High Throughput Microscopy – Image Acquisition
Cells were imaged using the Cell Lab IC-100 Image Cytometer
(IC-100; Beckman Coulter) platform that consists of 1) Nikon
Eclipse TE2000-U Inverted Microscope (Nikon; Melville, NY); 2)
Chroma 82000 triple band filter set (Chroma; Brattleboro, VT); 3)
an imaging camera: Hamamatsu ORCA-ER Digital CCD camera
(Hamamatsu; Bridgewater, NJ); and 4) a focusing camera:
Photonics COHU Progressive scan camera (Photonics; Oxford,
MA). The microscope was equipped with a Nikon S Fluor 40X/
0.90NA objective and the imaging camera set to capture 8 bit
images at 262 binning (6726512 pixels; 26.0 mm
2 pixel size) with
4 images captured per field (DAPI, GFP/A488, dsRED2skl,
A647). In general, 49 to 64 images were captured per well for
image analysis.
High Throughput Microscopy – Image Analysis
Fig. 1A shows examples of typical images obtained with the IC-
100 microscope of normal GSFs (L7728, M7118, A4676) or GSFs
from AIS patients [marked as GSF strain 571 (AR mutant F764L),
691 (AR mutant R840C) and 851(AR mutant P766S)], stained
with DAPI, AR, and CellMask solution, at concentrations of
Mibolerone of 0 and 100 nM. While our initial AR studies using
HTM were based upon CytoShop (Beckman-Coulter) [14,15,33],
these approaches were refined in the current work with the more
AR HCA in AIS Profiling
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and Advanced Imagine Collections, Pipeline Pilot 7.5, Accelrys,
San Diego). Initially, the background signal was removed from all
images using plate- and channel-specific correction images,
generated by the sum projection of .600 randomly selected
images for each channel from the image set. This allows for a
pixel-by-pixel background subtraction that compensates any
consistent uneven background artifacts in the image set.
Furthermore, users are able to customize the degree of
background subtraction by applying a multiplier to each
correction image, useful for identification of objects such as nuclei
or cell borders. After background subtraction, nuclear masks were
generated using a combination of non-linear least squares and
watershed-from-markers image manipulations of the DAPI images
(Fig. 1B). Cell border masks were generated using the CellMask-
labeled images, and watershed-from-markers image manipula-
tions. Due to the spindly shape of the genital skin fibroblasts, a
maximal distance from the nucleus limit was placed on the
generated cell masks. Cell populations were filtered to achieve
uniformity, e.g., without cell aggregates, mitotic cells, apoptotic
cells, or cellular debris.
Applied gates were based upon 1) nuclear area; 2) nuclear
circularity [(4*p*area)/perimeter
2]; and, 3) DNA content (DAPI
sum of pixel intensities) (Fig. 1B). AR expression was determined
by quantifying the sum of pixel intensities in the AR channel
within the defined cell region for each cell. AR nuclear
hyperspeckling is the statistical variance in AR pixel intensity
within the nuclear mask. Accumulation of the AR-sensitive
probasin transcriptional reporter was determined by measuring
the sum of pixel intensities in the dsRED2skl channel within the
cell region for each cell. Finally, the degree of AR nuclear
translocation was determined by measuring the percent of total
AR signal localized within the nuclear mask. EC50 values were
calculated by plotting a simple scatter plot of response versus
ligand concentration using the SigmaPlot four parameter logistic
curve-fitting algorithm. Due to the nature of the curve-fitting
algorithm, for those responses that did not plateau, the response
observed at the highest concentration was assumed maximal.
Changes in nuclear translocation with ligand treatment are
reported as the percentage point change in the percent of the
signal in the nucleus compared to untreated samples (i.e.
%Treated=75.1, %Untreated=35.2, %Response=39.9). All other
responses with ligand treatment are reported at fold change
compared to untreated samples (i.e. ReporterTreated=1000,
ReporterUntreated=100, ReporterResponse=10). Determination of
significant differences between compounds was accomplished by
first performing an ANOVA analysis followed by a post-hoc
multiple comparison analysis with significance set at ,0.05.
Pearson’s correlations analysis was performed to verify the
relationship existing between AR nuclear hyperspeckling and
transcriptional activation in HeLa cells. For each mutant and
ligand used, a strong positive correlation between these two
parameters was confirmed, with R
2 values close to 1, regardless of
the ligand or AR construct used. An example of this analysis for
HeLa cells stably transfected with wild type AR, AR-F764L, AR-
R840C or ARP766S and treated with DHT is shown in Fig. 2. In
this experiment, the R
2 value ranged between 0.85 and 0.999, and
p values were ,0.0001.
Results
NC-TDI of AR Mutants
NC-TDI is an important event in the regulation of AR activity
[34], and improper regulation of this interaction could be involved
in the abnormalities of the AIS mutations examined here. When
wild type AR was examined with T, DHT, R1881 and
Mibolerone used at 0.2–200 nM, all compounds were able to
induce an increase in luciferase activity at the lowest concentration
(0.2 nM; Fig. 3). The maximal responses of the tested compounds
ranged between a 3.2-fold increase and a 7.7-fold increase (T –
6.4, DHT – 7.7, Mb – 7.1, R1881 – 3.2). While the responses of
the weaker AR agonist T were dose-dependent, the three stronger
AR agonists (DHT, R1881, and Mb) lacked a dose-dependent
response, and reached their plateau at subnanomolar concentra-
tions. AR-F764L did not respond to T and DHT, however it
responded partially to R1881 (1.8-fold at 200 nM), and maximally
Figure 1. Androgen Receptor High Content Analysis (AR HCA). A, Sample of untreated or treated (with 100 nM Mibolerone) GSF images
captured with the IC-100 microscope showing three controls (L7728, M7118, A 4676), and three AIS patients [indicated as GSF strain 571 (AR mutant
F764L), 691 (AR mutant R840C) and 851(AR mutant P766S)]. For each experimental condition, the first rows show DAPI, AR, and cell mask staining. B:
Pipeline Pilot handling of the fluorescent images, starting from identification of the nucleus, of the cell mask, to computation of the green channel
(i.e. AR staining) features under various experimental conditions.
doi:10.1371/journal.pone.0008179.g001
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to 50-60% of wild type receptor at 0.2 and 200 nM of Mibolerone,
respectively. Thus, increasing the concentration of Mibolerone to
suprasaturating concentrations elicited a partial rescue of NC-TDI
in mutant AR- F764L (Fig. 3). Analysis of AR-R840C resulted in
significantly larger induction of the NC-TDI response when
compared to wild type AR with any of the ligands tested. The
response was dose-dependent with T and DHT, while it saturated
at 2 nM with the synthetic androgens Mb and R1881 (Fig. 3). In
contrast, there was a clear dose-dependent response to all ligands
tested for AR-P766S. The common denominator of the
experiments with AR-P766S was that doses of 200 nM of T,
DHT, Mib or R1881 were able to rescue the NC-TDI response to
the levels observed with wt AR at concentrations of 0.2 nM (Fig. 3).
Image Based Analysis of Wild Type AR Functions
HeLa cells. Emphasizing the specificity and reproducibility of
the HCA approach, our previous GFPAR HeLa results [15] were
duplicated with all three ligands. As shown in Fig. 4 and Table 1,
DHT, R1881, and Mb induced a significant increase in the
percent of the GFP signal in the nucleus (by approximately 30%)
with nM EC50 concentrations (DHT - 10.5 nM, R1881 - 0.8 nM,
Mb - 1.1 nM). All three agonists induced significant hypers-
peckling compared to vehicle control by approximately 50-fold, at
EC50 concentrations that, in agreement with previous data [35],
were significantly higher than for nuclear translocation (DHT:
29.1 nM; R1881: 28.5 nM; and, Mb: 29.4 nM). Induction of
hyperspeckling by the three ligands was tightly correlated to AR
transcriptional activity, with similarly high increases in reporter
accumulation (an average of 100-fold induction for each ligand) at
similar EC50 concentrations as observed for the hyperspeckling
response (DHT: 39.2 nM; R1881: 30.1 nM; and, Mb; 31.6 nM).
GSF cells from normal individuals. To directly visualize
endogenous AR expression in GSF cell lines, our standard
GFP-based approach was modified to include anti-AR im-
munofluorescence (Fig. 1A, 5, and Table 2). To better facilitate
direct comparisons between the GSF cell lines, results were
normalized to percent change or fold-change from vehicle-treated
controls. When treated with the standard panel of AR agonists, the
six normal GSF cell lines (M6382, L7728, M7118, A4676, S8558,
B8906) all demonstrated a dose-dependent increase in the percent
of the AR signal found in the nucleus. The average percent
increase with DHT, R1881 and Mibolerone in nuclear
translocation was 20.163.7%, 16.464.0% and 19.462.5%, and
this was achieved at EC50 concentrations of 0.1560.14,
0.2260.16 and 0.04660.041 nM, respectively (Fig. 5, Table 2).
The average increases in nuclear hyperspeckling and total AR
signal were 8- and 2-fold, respectively, and this was achieved at
subnanomolar EC50 values of the three ligands (Fig. 5, Table 2).
Image Based Analysis of AR- F764L Function
HeLa. We next applied the same technique to HeLa cells
stably expressing the AR-F764L mutation (Fig. 4, Table 1). When
cells were treated with the panel of agonists, ARF764L
translocated into the nucleus with similar increases in the
percent of nuclear GFP signal as wild type receptor (DHT: q
38%; R1881: q 36%; and, Mb: q 31%). However, the responses
were observed at higher EC50 concentrations, with the greatest
shift for the endogenous ligand DHT (DHT: 49.6 nM; R1881:
10.0 nM; and, Mb: 2.4 nM). Surprisingly, the hyperspeckling
response demonstrated a clear distinction between the three
compounds; DHT produced a weak hyperspeckling response at
elevated ligand concentrations (15-fold increase; EC50: 142 nM),
R1881 induced a significantly stronger response at even higher
ligand concentrations (77-fold increase; EC50: 233 nM) while Mb
was able to induce the highest levels of hyperspeckling (132-fold
increase) at an EC50 concentrations of 114 nM. Similarly to wild
type AR, transcriptional activity correlated with hyperspeckling.
Figure 2. Correlation analysis between nuclear hyperspeckling and transcriptional activity. HeLa cells were stably transfected with wild
type AR (A), AR-P766S (B), AR-F764L (C) and AR-R840C (D) and analyzed. Each point of the regression curve was derived from stimulation with
logarithmic concentrations of DHT (10
215 to 10
26 M).
doi:10.1371/journal.pone.0008179.g002
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Mb than R1881 and DHT (DHT: 6-fold; R1881: 18-fold; Mb: 36-
fold), and occurred at higher EC50 concentrations than with the
wild type receptor (DHT: 102 nM; R1881: 160 nM; and, Mb:
87 nM).
GSF. When we examined the nuclear translocation response
in GSF cells harvested from a patient harboring the F764L
mutation (Figure 6, Table 3), both R1881 and Mb were able to
induce a normal response (17.0% and 20.9% increase), whereas
the effect of DHT was below the range found in normal samples
(6.5% increase). In addition, the minor DHT respon se required
significantly higher concentration (EC50=35.3 nM) than the
agonist-induced responses in normal GSF cell lines. When the
hyperspeckling response was examined (Figure 6, Table 3), a
similar pattern emerged. Both R1881 and Mb induced strong
responses, nearly equivalent to that observed in the normal GSF
controls (5.7- and 9.7-fold increase) whereas DHT was weak (1.8-
fold increase). Again, the necessary concentration to induce a
DHT response was higher (EC50: 83.7 nM) than those needed for
the R1881 (EC50: 3.9 nM) or Mb (EC50: 3.5 nM), although all
EC50 concentrations were higher than the range observed in the
normal GSF control samples. When ligand dependent stabilization
of the F764L receptor was examined in GSFs, only R1881 and Mb
induced responses within the normal range of wild type GSF cells
(e.g., a 1.3- to 2.6-fold increase in total AR signal). These results
indicate that GSFs harboring the F764L mutation exhibited
reduced responsiveness to the endogenous ligand DHT, and that,
across all simultaneously evaluated measurements, a nearly
complete pharmacological rescue was possible with synthetic
agonists, particularly Mibolerone.
Image Based Analysis of AR- R840C Function
HeLa. When HeLa cells stably expressing the R840C PAIS
mutation were treated with the panel of agonists (Fig. 4, Table 1),
they also demonstrated the ability to achieve increases in nuclear
translocation similar to the wild type receptor (DHT: q 21%;
R1881: q 29%; and, Mb: q 29%), and at similar EC50
concentrations (DHT: 6.7 nM; R1881: 2.2 nM; and, Mb:
0.37 nM). However, because the receptor is significantly more
cytoplasmic in the untreated state, the relative maximal nuclear
translocation appears reduced (Fig. 4, Table 1). There was
reduced ability to induce hyperspeckling (DHT: 7-fold increase;
R1881: 11-fold increase; and, Mb: 8-fold increase), however,
responses occurred at lower EC50 concentrations compared to the
wild type receptor (DHT: 7.6 nM; R1881: 11.7 nM; and, Mb:
4.3 nM). Transcriptional activation mirrored the hyperspeckling
results, with only minor increases (DHT: 9-fold; R1881: 14-fold;
Mb: 11-fold) at EC50 concentrations below those observed with
the wild type receptor (DHT: 7.8 nM; R1881: 9.1 nM; and, Mb:
8.0 nM).
GSF. All three compounds tested induced significant nuclear
translocation responses (14.8% to 17.5% increase), in the range
Figure 3. NH2-COOH-terminal domain interaction (NC-TDI) assay. A segment containing AR 1-660 was fused to the VP16 TAD domain of
plasmid pFN10A CheckMate
TM/FlexiH Vector Mammalian Two-Hybrid System, Promega (Madison, WI), while segments AR 624-919 (wild type or
containing mutations F764L, R840C, and P766S) were fused to the to the Gal4-DBD domain of plasmid pFN11A. One day before transfection, 1.5610
6
HeLa cells were seeded into a 60 mm dish. Cells were co-transfected with 1.3 ug of pFN11A-AR624-919, 1.3 ug of pFN10A-1-660, 1.3 ug of pGL4.31
(containing five GAL4 binding sites upstream of a minimal TATA box, which is upstream of a firefly luciferase gene that acts as a reporter for
interactions between proteins), and 1 ng of phRL-TK carrying the Renilla luciferase gene. After 12 hours of transfection, cells were trypsinized and
equally seeded into nine wells of a 12 well plate, with one well treated with vehicle and others with various concentration of different ligand. After
24 h of treatment, luciferase activity was assayed with the Promega Dual Glo assay kit, using a luminometer (PerkinElmer). Data represent the
average6SD of three independent experiments, are expressed as fold-induction c/w negative control, and represent the units of firefly luciferase
corrected for the units of renilla luciferase detected in the same plate.
doi:10.1371/journal.pone.0008179.g003
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PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8179Figure 4. Dose-dependent effects of three AR agonists on AR nuclear translocation, nuclear hyperspeckling, and transcriptional
reporter gene activity. HeLa cells were stably transfected with wtAR (A), AR F764L (B), AR-R840C (C) and AR-P766S (D) and transiently transfected
with the reporter pARR2PB-dsRED2skl. Cells were maintained in 5% SD-FBS media for 12 hr and treated with the indicated compounds for 18 hr in
5%SD-FBS. Tested compounds given at logarithmic concentrations (10
214 to 10
25 M) include the following AR agonist: DHT (-#-),Mibolerone (-n-),
and R1881(-%-).
doi:10.1371/journal.pone.0008179.g004
AR HCA in AIS Profiling
PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8179observed in normal GSFs, at EC50 of 0.14-0.61 nM (Fig. 6,
Table 3). In contrast, only a moderate response in hyperspeckling
was observed (2.8- to 3.9-fold increase), at normal EC50
concentrations (EC50: 0.38–0.47 nM). Ligand-dependent stabili-
zation of the receptor occurred with all three compounds in a way
that was similar to normal GSF samples (1.8- to 2.3-fold; EC50:
0.17–0.55 nM). In general, in this cell line the results indicate that
agonist binding to AR-R840C generates normal nuclear
translocation and receptor stabilization, but significantly reduced
ability of AR to establish subnuclear hyperspeckling [15].
Image Based Analysis of AR-P766S Function
HeLa. All three agonists induced significant nuclear
translocation, hyperspeckling and transcriptional activation of
AR-P766S to wild-type AR levels, however, these responses were
observed at significantly higher concentrations of ligand (Fig. 4,
Table 1). In contrast to the F764L mutation, differential ligand
selectivity was absent in AR-P766S.
GSF. All three agonists induced significant nuclear translo-
cation (14.3%–20.7%) when used at higher concentrations (EC50:
1.2–3.2 nM) in GSFs harboring the AR-P766S mutation (Fig. 6,
Table 3). This was associated with marked hyperspeckling
responses (8.0- to 11.4-fold increase; EC50: 5.1–15.7 nM), and
receptor stabilization (e.g., 1.8- to 2.2-fold increase; EC50: 2.7–
5.9 nM). Overall, GSF AR-P766S was similar to GSF AR-F764L.
It showed reduced ligand sensitivity, although responsiveness was
complete, and not ligand-specific.
Discussion
We hypothesized that AR point mutations localized in the
ligand binding domain and associated with normal
3H-DHT Bmax
and Kd may be reversible, and proved this by using the new AR
HCA technology and conventional assays, such as NC-TDI. HCA
not only proved to be a powerful tool to understand the functional
abnormalities of AR mutations directly in patient-derived
specimens, but was also utilized to predict clinical responses to a
variety of experimental treatments.
NC-TDI
Experiments were performed to establish if the three mutants
were affected by an impairment of the NH2-COOH terminal
interaction, and if so, if this impairment would be amenable to
normalization using conditions that enhance stability of binding,
for instance by increasing concentrations of natural or synthetic
AR agonists. NC-TDI was impaired in the two mutations
associated with increased ligand-receptor dissociation rate; AR-
F764L and AR-P766S. ARF764L demonstrated a ligand-
dependent partial rescue of NC-TDI to approximately 50% of
wild type, at high concentrations (e.g.: 200 nM) of Mibolerone,
but not of R1881 and DHT. AR-P766S demonstrated a
complete rescue of NC-TDI with all four ligands, in a way that
was proportional to the concentration used, and reached
complete normalization at 200 nM. These data confirmed that
notion that abnormal NC-TDI is a hallmark of increased ligand-
receptor dissociation rate [36], and suggested that a stabilization
of ligand-receptor interaction occurred at higher concentrations
of ligand. That NC-TDI recovery was only partial and ligand-
dependent in F764L was surprising. This observation may be
related to the fact that F764 makes direct ligand contact [37],
and its replacement by ligand may alter the conformation of the
ligand binding pocket which results in increased affinity for
ligands other than DHT. The R840C mutation demonstrated
increased NC-TDI’s with all ligands and concentrations tested
compared to wild type. We knew from the outset that AR-
R840C affected
3H-DHT binding causing thermolability, not
Table 1. Calculated Maximal and EC50 Responses of AIS Mutations in HeLa Cells.
Response Untreated DHTMax DHTEC50 R1881Max R1881EC50 MbMax MbEC50
HeLa Wild Type
Percent Signal in Nucleus 49.064.5 75.662.1 10.561.9 81.261.9 0.860.5 80.561.9 1.160.7
Hyperspeckling 20.5610.1 950643 29.164.1 1138666 28.564.1 1101661 29.465.2
Transcriptional Activity 1.0641 0 5 623 9 . 2 65.1 11261.5 30.164.4 11361.4 31.663.9
HeLa F764L
Nuclear Translocation 42.260.9 80.361.0 49.668.4 77.161.3 10.061.6 73.260.8 2.460.3
Hyperspeckling 7.361.8 118631 4 2 617 561610 233616 965681 1 4 64
Transcriptional Activity 2.660.7 14.560.9 72.6625.9 46.460.5 15067 92.962.2 87.5611.2
HeLa R840C
Nuclear Translocation 35.260.8 56.260.8 6.761.4 64.160.9 2.260.12 63.761.1 0.3760.12
Hyperspeckling 32.667.3 22267.0 7.661.3 361620 11.762.7 269620 4.362.0
Transcriptional Activity 3.26.74 28.560.8 7.861.0 44.061.7 9.161.5 35.361.4 8.061.6
HeLa P766S
Nuclear Translocation 43.261.2 79.262.1 151612 76.561.9 165615 78.961.5 165615
Hyperspeckling 12.662.3 752625 251633 801638 283621 785630 264610
Transcriptional Activity 1.163.1 9562.3 243691 0 1 622 6 8 619 9862.2 245615
Values calculated by applying the 4-parameter curve fit algorithm available in SigmaPlot to multiple replicate experiments and represent Mean6S.E.M. All data are
presented as absolute numerical measurements.
Calculated maximal responses from AR HCA. EC50 values are presented for Nuclear Translocation, Hyperspeckling and Transcriptional Activity after stimulation with
three AR agonists (DHT, Mibolerone and R1881) in HeLa transfected with wild type AR, AR-F764L, AR-R840C and AR-P766S. EC50 represents the nM concentration of
agonist that provokes a response halfway between the baseline and maximal induction. Maximal response achieved with each agonist for each HTM parameter is
expressed as % signal present in the nucleus for Nuclear Translocation, as fold-induction from time point 0 for Hyperspeckling and Transcriptional Activity.
doi:10.1371/journal.pone.0008179.t001
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PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8179Figure 5. Dose dependent effects of three AR agonists on AR nuclear translocation, nuclear hyperspeckling and total AR. Data of
fold-increase are presented from 6 genital skin fibroblasts cell lines obtained form normal individuals at the time of circumcision. Cells were
maintained in 5% SD-FBS media for 12 hr and treated with the indicated compound for 18 hr in 5%SD-FBS. Tested compounds given at logarithmic
concentrations (10
214 to 10
25 M) include the following AR agonist: DHT (-#-), Mibolerone (-n-), and R1881(-%-).
doi:10.1371/journal.pone.0008179.g005
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have been a surprise to find that NC-TDI was unaffected in AR-
R840C. The mechanism of androgen insensitivity in the context
of an AR mutation showing increased NC-TDI is unclear.
Because AF2 is important not only for NC-TDI, but also for p-
160 coactivators recruitment [38], it could be speculated that the
increased interaction between AF2 and the N-terminus observed
in AR-R840C may be associated with improper recruitment of
p-160 coactivators, and thus decreased AR transcriptional
activity. Finally, as the transient expression of the wt and
mutant AR fusions in the N-C assay precludes measurement of
absolute AR levels per cell, we cannot dismiss the possibility that
t h eo b s e r v e di n c r e a s ei nN - Ci n t e r a c t i o n sm a yb ei n f l u e n c e db y
stabilization of the LBD by a type, or concentration, of ligand.
Given the preponderance of our other data, this less interesting
possibility seems remote.
HCA Experiments in Hela Transfected with Wild Type AR
vs. GSF from Normally Virilized Individuals
HCA activities measured in primary GSF cultures from six
normal patients that were used as a control were within a relatively
small interval. These minor differences probably reflect a unique
intracellular equilibrium of molecules regulating AR activation, or
polymorphisms of the polyglutamine repeat of AR exon 1. It is also
possible that the different HCA activities observed in these cell
lines reflect different degrees of normal virilization that are present
in the general population.
A number of reproducible, cell line-dependent differences were
detected in the control groups between HeLa and GSF. First,a s
previously described [15], EC50 for ligand-dependent nuclear
translocation were higher compared with hyperspeckling and
transcriptional activity in HeLa-AR cells using R1881 and
Mibolerone (by a factor of approximately 30-fold), or DHT (by
Table 2. Calculated Max and EC50 Responses of Normal GSF Cell Lines.
Response Untreated DHTMax DHTEC50 R1881Max R1881EC50 MbMax MbEC50
GSF M6382 (Normal)
Percent Signal in Nucleus 51.263.2 70.160.4 0.1460.01 70.060.9 0.08060.023 73.160.5 0.1260.01
Hyperspeckling 7.561.2 76.562.6 0.4560.10 77.761.6 0.3160.04 92.261.2 0.2160.02
Total AR 74.965.4 224625 0.4960.58 19169 0.1960.10 21067 0.1860.06
GSF L7728 (Normal)
Nuclear Translocation 50.262.1 65.060.5 0.04760.011 63.161.0 0.2660.13 69.160.5 0.01560.003
Hyperspeckling 25.063.7 162610 0.07760.044 12465 0.07760.036 12866 0.09760.030
Total AR 12.563.1 31.860.8 0.01260.004 33.661.4 0.2860.12 31.260.5 0.08460.013
GSF M7118 (Normal)
Nuclear Translocation 31.461.9 50.961.5 0.01360.009 47.260.8 0.1960.07 48.160.9 0.01360.007
Hyperspeckling 6067.1 606618 0.1260.03 560627 0.6760.20 586635 0.03060.016
Total AR 82610 13365 0.1660.10 13664 0.3660.15 13864 0.03360.01
GSF A4676 (Normal)
Nuclear Translocation 32.162.1 51.660.6 0.4960.13 49.261.4 0.1160.06 48.960.6 0.05260.016
Hyperspeckling 4366.2 469610 0.8460.17 473610 0.1460.03 464639 0.03260.023
Total AR 53614 12563 0.3360.14 10864 0.03060.010 12262 0.1460.04
GSF S8558 (Normal)
Nuclear Translocation 35.263.1 58.160.4 0.3160.05 47.260.8 0.1960.07 55.160.5 0.02860.006
Hyperspeckling 3566.6 374.568 0.9060.40 33766 0.9260.14 35567 0.1860.04
Total AR 5069 11162 1.060.2 11463 0.9560.21 11462 0.8560.22
GSF B8906 (Normal)
Nuclear Translocation 39.260.2 64.360.4 0.3260.03 61.560.5 0.5360.11 61.360.7 0.05160.017
Hyperspeckling 4565.2 40567 0.5360.08 343651 . 3 60.2 40166 0.1760.03
Total AR 5965 12361 1.760.3 11261 0.6360.08 12866 0.3860.09
Average Normal Response DHTChange DHTEC50 R1881Change R1881EC50 MbChange MbEC50
Nuclear Translocation (% Point change) 20.161.4 0.1560.06 16.561.6 0.2360.07 19.461.0 0.04660.016
Hyperspeckling (fold change) 9.660.7 0.4960.14 8.860.9 0.5760.20 9.561.0 0.1260.04
Total AR (fold change) 2.360.2 0.6160.26 2.260.2 0.4460.15 2.360.2 0.2860.12
Values calculated by applying the 4-parameter curve fit algorithm available in SigmaPlot to multiple replicate experiments. For individual cell lines, all data are
presented as absolute numerical measurements. For the average normal response, nuclear translocation is reported as the percentage point change from untreated
samples whereas hyperspeckling and total AR is reported as fold change from untreated samples.
Calculated maximal responses from AR HCA. EC50 values for Nuclear Translocation, Hyperspeckling and Total AR increase after stimulation with three AR agonists (DHT,
Mibolerone and R1881) in GSF from 6 normal individuals (M6382, L7728, M7118, A4676, S8558, B8906). EC50 represents the nM concentration of agonist that provokes a
response halfway between the baseline and maximal induction. Maximal response achieved with each agonist for each HTM parameter is expressed as % signal present
in the nucleus for Nuclear Translocation, as fold-induction from time point 0 for Hyperspeckling and Total AR content.
doi:10.1371/journal.pone.0008179.t002
AR HCA in AIS Profiling
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8179a factor of approximately 3-fold). In contrast no such difference
was present in GSF cells. Second, the EC50’s for hyperspeckling
were lower in GSF compared with HeLa by a factor of
approximately 70-fold. Third, the fold-induction of hyperspeck-
ling (a surrogate of transcriptional activity) was lower by a factor of
5-fold in GSF cells compared to HeLa-AR. The reasons for these
discrepancies are not clear. The first discrepancy may be related to
decreased ability of ligand-bound AR to interact with the
machinery necessary for nuclear import in HeLa cells, or to the
presence of a competing androgen-binding protein in the cytosol
but not the nucleus of HeLa, so that higher concentrations of
androgen would be necessary to complete functions that take place
in the cytoplasm, such as nuclear import, but not in the nucleus,
such as hyperspeckling or transcriptional activity. The third
discrepancy may be related to decreased transcriptional activity in
GSF reported by others [39], or to the preponderance in these cell
lines of AR co-repressors [40].
AR-F764L
These studies have shown that the recovery of AR-F764 activity
(e.g.: 45% of control) occurs in a Mibolerone-dependent way.
Similar results were obtained in GSF containing ARF764L or
transfected HeLa; the main difference being that Mibolerone was
more effective in GSF, with a recovery of hyperspeckling, a
surrogate marker of transcription, at 100% of control levels. These
studies reconcile the CAIS phenotype of this patient with the fact
Figure 6. Dose dependent effects of three AR agonists on AR nuclear translocation, nuclear hyperspeckling and total AR fold-
increase. Data is presented from genital skin fibroblasts cell lines obtained from AIS patients with AR mutations AR-F764L (GSF571), AR-R840C
(GSF840) and AR-P766S (GSF851). Cells were maintained in 5% SD-FBS media for 12 hr and treated with the indicated compound for 18 hr in 5%SD-
FBS. Tested compounds given at logarithmic concentrations (10
214 to 10
25 M) include the following AR agonist: DHT (-#-), Mibolerone (-n-), and
R1881(-%-).
doi:10.1371/journal.pone.0008179.g006
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exposed to the endogenous ligand DHT, which is inactive with
AR-F764L. A Mibolerone-specific recovery of function argues that
this agonist fits inside the mutated ligand-binding pocket of AR-
F764L more properly than the physiologic ligand DHT.
Stabilization of the receptor-ligand complex with high doses of
Mibolerone rescued NC-TDI to 50% of control, and this was
associated by improved ligand retention in the ligand-binding
pocket of the receptor, and by an increase in transcription.
AR-P766S
We observed complete recovery of AR NC-TDI and HCA
functions with pharmacologic concentrations of DHT, R1881 and
Mibolerone for mutant AR-P766S. Because the interaction
between ligands and AR-P766S was highly unstable at physiologic
concentrations, NC-TDI and transcription were compromised to
the point that the patient developed a CAIS phenotype.
Supraphysiologic concentrations of the three ligands improved
ligand-receptor stability, and normalized NC-TDI and transcrip-
tional activity to control levels.
AR-R840C
HCA analysis in HeLa and GSF cells showed that nuclear
translocation of AR-R840C could be almost normalized at higher
concentration of each ligand, however neither hyperspeckling nor
transcriptional activity were recovered. Because this mutation was
not associated with instability of receptor-ligand binding, lack of
response to experimental conditions coupled with increased
receptor-ligand stability was not surprising. As stated above, the
presence of increased NC-TDI may be associated with decreased
recruitment of coactivators and decreased transcriptional activity.
In conclusion these studies have generated several new
concepts. First, AIS mutations with normal Kd,B max, and
increased ligand dissociation rate can be rescued. In contrast,
other mutations with a slightly different phenotype (i.e. normal Kd,
Bmax, ligand dissociation rate, but abnormal thermostability) were
not rescued. Thus, to this point the biochemical signature of AR
mutations that can be rescued consists in normal Kd,B max, and
increased ligand dissociation rate. In support of these observations,
the PAIS patients who responded to treatment in the paper of
Grino [6,10] had an AR mutation with this biochemical signature.
Second: mutations with normal Kd and Bmax and increased ligand
dissociation rate are associated with decreased NC-TDI. NC-TDI
is a surrogate of ligand-receptor binding stability, thus such
mutations can be rescued by using conditions that increase ligand-
receptor binding stability, such as use of pharmacologic doses of
natural or synthetic ligands. Third: These studies prove the fact
that HCA can generate in a short period of time useful
information to direct personalized medicine for patients affected
by AIS. The extent that these studies can be generalized will be
determined by AR HCA studies of additional patients with similar
phenotypes.
How AR HCA Data Could Be Used in a Clinical Setting
More studies are needed with additional cell lines before direct
translation into clinical practice. Safety will be an important issue,
particularly for the synthetic agonists, which are not FDA-
approved. The CAIS phenotype of patients AR-P766S and AR-
F764L argues against treating these patients, because 100% of
them reared as females maintained throughout life a female
gender identity [41]. Nevertheless, the prediction is that significant
virilization may have occurred after observing the in vitro response
of AR-P766S and AR-F764L. PAIS patients would clearly be the
first beneficiaries of this technology. Whether the small improve-
ment in AR activity observed at pharmacologic doses of agonists
for AR-R840C would have resulted in an improvement of the
PAIS phenotype of this patient remains unknown; however,
experience with similarly undervirilized individuals argues that
even small responses improve the outcome of surgical repairs [6].
In conclusion, this work represents a step forward toward the
utilization of modern high-speed microscopic techniques for the
diagnosis and treatment of diseases related to AR. It will be
Table 3. Calculated Max and EC50 Responses of AIS GSF Cell Lines.
Response Untreated DHTMax DHTEC50 R1881Max R1881EC50 MbMax MbEC50
GSF 571 (F764L)
Nuclear Translocation 37.264.5 43.060.1 35.364.3 54.260.7 0.3560.13 58.160.2 0.4760.04
Hyperspeckling 72.167.6 130648 3 . 7 618.4 411616 3.961.4 69969 3.560.4
Total AR 45.162.2 58.860.7 33.6610.0 73.262.9 3.262.8 99.462.0 3.460.9
GSF 691 (R840C)
Nuclear Translocation 20.161.1 37.660.8 0.5160.14 37.060.4 0.1460.02 34.960.3 0.6160.07
Hyperspeckling 15.364.1 51.261.2 0.4760.09 43.161.5 0.3860.13 59.261.8 0.4460.12
Total AR 40.161.9 78.662.8 0.3960.17 71.462.1 0.5460.20 93.065.2 0.5560.31
GSF 851 (P766S)
Nuclear Translocation 30.162.1 50.860.5 1.260.2 44.460.6 3.261.0 44.961.1 3.261.9
Hyperspeckling 25.160.9 28663 5.160.3 20166 15.763.3 224651 3 62
Total AR 135632 294627 2.760.4 239655 . 9 62.9 28365 2.860.8
Values calculated by applying the 4-parameter curve fit algorithm available in SigmaPlot to multiple replicate experiments. All data are presented as absolute numerical
measurements.
Calculated maximal responses from AR HCA.
EC50 values for Nuclear Translocation, Hyperspeckling and Total AR increase after stimulation with three AR agonists (DHT, Mibolerone and R1881) in GSF from AIS
patients with AR mutations F764L, R840C and P766S. EC50 represents the nM concentration of agonist that provokes a response halfway between the baseline and
maximal induction. Maximal response achieved with each agonist for each HTM parameter is expressed as % signal present in the nucleus for Nuclear Translocation, as
fold-induction from time point 0 for Hyperspeckling and Total AR content.
doi:10.1371/journal.pone.0008179.t003
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global effects of AR rescue using different concentrations of ligand,
or with ligands other than the endogenous AR agonists. Future
investigation will continue to analyze AR malfunction in AIS and
other clinical conditions, such as prostate cancer, hypospadias,
cryptorchidism and sarcopenia.
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